Nayyra Fatani1, Dave L Dixon2, Benjamin W Van Tassell2, John Fanikos3, Leo F Buckley4. 1. Department of Clinical Pharmacy, College of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia; Department of Pharmacy Practice, MCPHS University, Boston, Massachusetts, USA; Department of Pharmacy Services, Brigham and Women's Hospital, Boston, Massachusetts, USA. 2. Department of Pharmacotherapy and Outcomes Science, Virginia Commonwealth University, Richmond, Virginia, USA. 3. Department of Pharmacy Services, Brigham and Women's Hospital, Boston, Massachusetts, USA. 4. Department of Pharmacy Services, Brigham and Women's Hospital, Boston, Massachusetts, USA. Electronic address: LFBuckley@bwh.harvard.edu.
Abstract
BACKGROUND: Standard blood pressure control metrics may not account for fluctuations in blood pressure over time. OBJECTIVES: This study sought to estimate the independent association between time in systolic blood pressure target range and major adverse cardiovascular events among adults with hypertension. METHODS: This study was a post hoc analysis of SPRINT (Systolic Blood Pressure Intervention Trial), a randomized clinical trial that compared intensive (<120 mm Hg) and standard (<140 mm Hg) systolic blood pressure treatment interventions in adults with hypertension and high cardiovascular risk. Target range was defined as 110 to 130 mm Hg and 120 to 140 mm Hg for the intensive and standard arms, respectively. Time in target range was estimated over the first 3 months of follow-up using linear interpolation. The association between time in target range with major adverse cardiovascular events was estimated using adjusted Cox proportional hazards regression models. RESULTS: Participants with greater time in target range were younger, had lower 10-year cardiovascular risk and lower baseline systolic blood pressure, and were more likely women and statin users. Each 1-SD increase in time in target range was significantly associated with a decreased risk of first major adverse cardiovascular event in fully adjusted models. Time in target range remained significantly associated with major adverse cardiovascular events despite adjustment for mean systolic blood pressure or systolic blood pressure variability. Among participants with mean systolic blood pressure at or below target, time in target range remained associated with major adverse cardiovascular events. CONCLUSIONS: Time in systolic blood pressure target range independently predicts major adverse cardiovascular event risk.
BACKGROUND: Standard blood pressure control metrics may not account for fluctuations in blood pressure over time. OBJECTIVES: This study sought to estimate the independent association between time in systolic blood pressure target range and major adverse cardiovascular events among adults with hypertension. METHODS: This study was a post hoc analysis of SPRINT (Systolic Blood Pressure Intervention Trial), a randomized clinical trial that compared intensive (<120 mm Hg) and standard (<140 mm Hg) systolic blood pressure treatment interventions in adults with hypertension and high cardiovascular risk. Target range was defined as 110 to 130 mm Hg and 120 to 140 mm Hg for the intensive and standard arms, respectively. Time in target range was estimated over the first 3 months of follow-up using linear interpolation. The association between time in target range with major adverse cardiovascular events was estimated using adjusted Cox proportional hazards regression models. RESULTS: Participants with greater time in target range were younger, had lower 10-year cardiovascular risk and lower baseline systolic blood pressure, and were more likely women and statin users. Each 1-SD increase in time in target range was significantly associated with a decreased risk of first major adverse cardiovascular event in fully adjusted models. Time in target range remained significantly associated with major adverse cardiovascular events despite adjustment for mean systolic blood pressure or systolic blood pressure variability. Among participants with mean systolic blood pressure at or below target, time in target range remained associated with major adverse cardiovascular events. CONCLUSIONS: Time in systolic blood pressure target range independently predicts major adverse cardiovascular event risk.
Authors: Donald Clark; Stephen J Nicholls; Julie St John; Mohamed B Elshazly; Haitham M Ahmed; Haitham Khraishah; Steven E Nissen; Rishi Puri Journal: JAMA Cardiol Date: 2019-05-01 Impact factor: 14.676
Authors: Walter T Ambrosius; Kaycee M Sink; Capri G Foy; Dan R Berlowitz; Alfred K Cheung; William C Cushman; Lawrence J Fine; David C Goff; Karen C Johnson; Anthony A Killeen; Cora E Lewis; Suzanne Oparil; David M Reboussin; Michael V Rocco; Joni K Snyder; Jeff D Williamson; Jackson T Wright; Paul K Whelton Journal: Clin Trials Date: 2014-06-05 Impact factor: 2.486
Authors: Paul K Whelton; Robert M Carey; Wilbert S Aronow; Donald E Casey; Karen J Collins; Cheryl Dennison Himmelfarb; Sondra M DePalma; Samuel Gidding; Kenneth A Jamerson; Daniel W Jones; Eric J MacLaughlin; Paul Muntner; Bruce Ovbiagele; Sidney C Smith; Crystal C Spencer; Randall S Stafford; Sandra J Taler; Randal J Thomas; Kim A Williams; Jeff D Williamson; Jackson T Wright Journal: J Am Coll Cardiol Date: 2017-11-13 Impact factor: 24.094
Authors: Paul Muntner; Shakia T Hardy; Lawrence J Fine; Byron C Jaeger; Gregory Wozniak; Emily B Levitan; Lisandro D Colantonio Journal: JAMA Date: 2020-09-22 Impact factor: 56.272
Authors: Elsayed Z Soliman; Walter T Ambrosius; William C Cushman; Zhu-Ming Zhang; Jeffrey T Bates; Javier A Neyra; Thaddeus Y Carson; Leonardo Tamariz; Lama Ghazi; Monique E Cho; Brian P Shapiro; Jiang He; Lawrence J Fine; Cora E Lewis Journal: Circulation Date: 2017-05-16 Impact factor: 29.690
Authors: Chike C Nwabuo; Yuichiro Yano; Henrique T Moreira; Duke Appiah; Henrique D Vasconcellos; Queen N Aghaji; Anthony Viera; Jamal S Rana; Ravi V Shah; Venkatesh L Murthy; Norrina B Allen; Pamela J Schreiner; Donald M Lloyd-Jones; João A C Lima Journal: JAMA Cardiol Date: 2020-07-01 Impact factor: 14.676
Authors: Michael Doumas; Costas Tsioufis; Ross Fletcher; Richard Amdur; Charles Faselis; Vasilios Papademetriou Journal: J Am Heart Assoc Date: 2017-11-03 Impact factor: 5.501
Authors: Josep Sola; Meritxell Cortes; David Perruchoud; Bastien De Marco; Melvin D Lobo; Cyril Pellaton; Gregoire Wuerzner; Naomi D L Fisher; Jay Shah Journal: Front Med Technol Date: 2022-05-17
Authors: Yook Chin Chia; Wan Azman Wan Ahmad; Alan Yean Yip Fong; Azhari Rosman; Abdul Rashid Abdul Rahman; Gim Hooi Choo; Soo Kun Lim; Mohammad Zawawi Abu Bakar; Tiong Kiam Ong Journal: Hypertens Res Date: 2022-06-01 Impact factor: 5.528
Authors: David E Kandzari; Felix Mahfoud; Michael A Weber; Raymond Townsend; Gianfranco Parati; Naomi D L Fisher; Melvin D Lobo; Michael Bloch; Michael Böhm; Andrew S P Sharp; Roland E Schmieder; Michel Azizi; Markus P Schlaich; Vasilios Papademetriou; Ajay J Kirtane; Joost Daemen; Atul Pathak; Christian Ukena; Philipp Lurz; Guido Grassi; Martin Myers; Aloke V Finn; Marie-Claude Morice; Roxana Mehran; Peter Jüni; Gregg W Stone; Mitchell W Krucoff; Paul K Whelton; Konstantinos Tsioufis; Donald E Cutlip; Ernest Spitzer Journal: Circulation Date: 2022-03-14 Impact factor: 29.690